Newsletter | March 2025
Samsung Biologics
Innovation, passion and an unwavering dedication to find breakthrough solutions in biomedicines.
Harmonized toward ADC expertise
Antibody-drug conjugates (ADCs) continue to garner attention for their targeted therapeutic effects and promising clinical applications. Now with over a dozen FDA-approved ADCs in the market and many more candidates, partnership with trusted CDMOs is ever more key for scaling up production. Samsung Biologics’ new ADC facility paired with process development and manufacturing expertise seeks to support clients’ ambitious timelines for high-quality product delivery. Learn more
People Excellence: Driver of Samsung Biologics' growth
People are at the core of what we value at Samsung Biologics. We continue to build on people excellence, offering various opportunities for our employees to learn and grow while supporting them in sustaining a healthy lifestyle. Read more about how our employees pursue growth in a rapidly growing and constructive work environment.
COMPANY NEWS
Samsung Biologics named winner of 2025 CDMO Leadership Awards
Samsung Biologics received the CDMO Leadership Awards presented by Outsourced Pharma. The company was named a winner in the ‘Biologics – Global’ category and also received the “Best Facility” award this year. Samsung Biologics has received the CDMO leadership award for 12 consecutive years. Read more
BIO INSIGHT
Understanding and mitigating oxygen heterogeneity in large-scale bioreactors
Oxygen distribution is a key element for ensuring optimal conditions for cell growth and product formation in large-scale bioreactors, but managing its variability can be challenging. This whitepaper explores the factors that contribute to oxygen heterogeneity and how can they be controlled to ensure process consistency. Read more
Recommended by LinkedIn
Overcoming challenges to high-concentration formulation development
With increasing demand for high-concentration antibodies, developers must address challenges such as viscosity, phase separation, and protein aggregation—all of which can impact formulation performance and production. Read our whitepaper to learn how the S-HiCon™ platform applies advanced analytical techniques and risk mitigation strategies to optimize high-concentration formulations.
Advanced LC-MS technology for enhanced HCP detection in complex biotherapeutics
Host cell proteins (HCPs) are impurities in biotherapeutics that can impact drug quality and patient safety. Common methods like ELISA and LC-MS often fall short in detecting low-abundant HCPs, which pose risks to drug efficacy and stability. Read the full article to learn how this innovation enhances HCP detection and improves biotherapeutic safety and quality.
The future of bispecific antibodies
Developers of complex molecules must prioritize both the efficacy and developability of intricate biologics—for instance, bispecific antibodies. Maintaining these critical characteristics of a bsAb requires versatile platforms and technologies, but more importantly, experts experienced in leveraging these advanced tools to advance difficult-to-express molecules to the next level. Our bsAb experts—Jina Kim and Haejin Kweon—discuss their cumulative industry knowhow of how a bsAb molecule can be developed in full without compromising quality. Read More
Beyond capacity: biopharma companies need agile manufacturing partners
Agility is more than speed. For a CDMO, it means building technical capabilities to meet evolving biopharmaceutical demand as well as assuring clients that manufacturing plants will be ready when they need it. James Choi, Executive Vice President, Chief Marketing Officer, and Head of Project Management and Global Public Affairs, discusses key characteristics CDMOs should adopt to achieve client satisfaction with the Manufacturing Chemist. Read More
Navigating evolving mRNA challenges with the right partner
Messenger RNAs (mRNAs) have opened up a new frontier in developing innovative therapeutics beyond vaccines. At the same time, challenges regarding its intricacy in technology and quality procedures remain to be solved. Two of our veteran mRNA scientists, Sungyul Lee and Eunseo Lee, walk through a list of key technologies and earned know-how required to develop mRNA drugs right the first time. Read more
2025 pharma predictions
What are the trends shaping biopharma in 2025? ADC Process Development Director Song Young Kim shares his insights on overcoming ADC manufacturing and supply chain challenges. Read more
UPCOMING EVENTS